HUTCHMED Cancer Drug Savolitinib Granted Priority Review in China

source:

[1] HUTCHMED (00013)'s New Drug Application for Savolitinib has been accepted and granted Priority Review (https://www.aastocks.com/tc/stocks/news/aafn- ...)

HUTCHMED Cancer Drug Savolitinib Granted Priority Review in China

Related News

Corcept Therapeutics Plummets 48%, Marking Worst Day in 11 Years

NIO Plunges 5% as Chinese EV Stocks Lead Market Decline

Shandong Zhanggu Faces CSRC Probe Over Financial Disclosures